We put on a bullish bet in biotechs a couple of weeks ago and it quickly rolled over on us. The market had other ideas.
Now here we are, a couple of weeks later, and the biotech ETF $XBI finds itself mired in a range with rising implied volatility signaling elevated options premiums:
You need to have a subscription to access this content in full.
